These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67 related articles for article (PubMed ID: 1778325)
61. Calculation of efficacy of acellular pertussis vaccine from the number of pertussis patients and vaccinees in three areas. Ohkuni H; Yabiku M; Togawa M; Fukai K; Yosida I; Minekawa Y; Kitamura T Dev Biol Stand; 1991; 73():43-9. PubMed ID: 1778332 [TBL] [Abstract][Full Text] [Related]
62. Efficacy of acellular pertussis vaccine in Japan--comparison of two areas, one area where immunization started at 6 months and the other area at over 2 years of age--Regional Surveillance Committee on Tuberculosis and Infectious Diseases of Osaka. Ohkuni H; Kitaura T; Tamai T; Takasugi Y; Sugimoto T; Fukai K Tokai J Exp Clin Med; 1988; 13 Suppl():51-4. PubMed ID: 3273619 [TBL] [Abstract][Full Text] [Related]
63. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Gustafsson L; Hessel L; Storsaeter J; Olin P Pediatrics; 2006 Sep; 118(3):978-84. PubMed ID: 16950988 [TBL] [Abstract][Full Text] [Related]
65. Relationship between bacterial meningitis and acellular pertussis vaccine. Yabiku M; Ohkuni H; Shiomi M; Ishii T; Shimotuji T Dev Biol Stand; 1991; 73():315-21. PubMed ID: 1778325 [TBL] [Abstract][Full Text] [Related]
66. The epidemiology of bacterial meningitis occurring in a Pacific Island population. Carroll K; Carroll C P N G Med J; 1993 Sep; 36(3):234-42. PubMed ID: 8059550 [TBL] [Abstract][Full Text] [Related]